Introduction
Warfarin, a widely used oral anticoagulant, acts by inhibiting vitamin K-dependent coagulation factors and is used to treat several thromboembolic diseases, including atrial fibrillation, deep-venous thrombosis, pulmonary thromboembolism, heart valve replacement, and dilated cardiomyopathy (1, 2) . The clinical efficacy of warfarin is evaluated by measuring the international normalized ratio (INR) within the determined therapeutic range, which depends on the disease (3) . As long as the target INR is achieved and maintained, warfarin therapy has been proven to decrease the risk of thromboembolic events (4) . However, one of the foremost challenges in using warfarin is to maintain the target INR within the therapeutic range for the disease under treatment (5) . Supra-therapeutic INRs (>3.5) can cause minor or major bleeding. According to the results of previous studies, the most frequent complication of warfarin therapy is hemorrhage necessitating emergency department (ED) treatment (6, 7) .
In patients with elevated INRs, the treatment options are to stop warfarin therapy, administer oral or intravenous vitamin K, or administer intravenous fresh frozen plasma (FFP). Although FFP is not the first option for treating supra-therapeutic INRs, particularly in patients with major bleeding, it is widely used in EDs to rapidly normalize INRs. Although there is no clear evidence-based data on the dose of FFP required to successfully treat elevated INRs, previous guidelines have recommended 10-15 mL of plasma per kilogram of body weight (8, 9) . However, it is the standard dose of FFP to reduce various elevations in INR is not clear. Therefore, this study aimed to determine the effects of using a standard dose of FFP on INRs of patients with various elevations in INR from using warfarin.
Materials and Methods
This prospective study was conducted in the ED of a training and research hospital from February 2015 to January 2016. The local ethics committee approved the study, and the researchers obtained written informed consent from the patients or their legally authorized relatives.
The study included patients age 18 or older who were admitted to the ED with elevated INRs, either with or without bleeding and who had one or more indications for FFP treatment, which were defined as major bleeding and an elevated INR, minor bleeding that had been unstoppable despite appropriate intervention and an elevated INR, and highly elevated INR (>20) with or without any other complaints. The study excluded patients younger than the age of 18, those who did not receive FFP treatment, and those whose pre-and post-transfusion INRs were not measured.
After the patients were initially evaluated, their demographic data, clinical features, and laboratory findings, including pre-and post-transfusion INRs, were recorded. The standard dose of FFP used was 3 units of FFP (900 mL). The median weight of our patients was 74 (min: 62, max: 85) and the mean of mL/kg of FFP body weight was 12. 
Statistical analysis
Statistical analyses were performed using Statistical Package for the Social Sciences version 15.0 (IBM SPSS Statistics; New York; USA). The Shapiro-Wilk test was used to assess the normal distribution of all parameters related to the patients. The patients' parametric data were expressed as mean and standard deviation (SD). The mean ΔINR were analyzed by one-way analysis of variance (ANOVA) in nondependent groups. Pearson's test was used to calculate the correlation between high pre-transfusion INRs and ΔINR. Finally, to estimate the ΔINR after an FFP transfusion, linear regression analysis was performed using the formula y=a+bx, where x=[pre-transfusion INR]. A p value of <0.05 was considered statistically significant.
Results
During the study period, 106 patients with elevated INRs were admitted to the ED. Of these, 74 did not receive FFP because they had no major bleeding or other indications; thus, they were excluded. This left 32 patients who both received FFP and whose pre-and post-transfusion INRs were measured. Of these 32 patients, 23 (71%) were women. The patients' mean age was 72.8±11.1 years. Table 1 shows the patients' demographic and clinical characteristics. The mean pre-transfusion INR, post-transfusion INR, and ΔINR were 10.6±5.3, 4.3±2.3, and 6.2±4.3, respectively.
Then, patients were categorized according to their pre-transfusion INRs; eight patients were categorized as having slightly elevated INR (INR=3-6), 12 were categorized as having moderately elevated INR (INR=6-9), and 12 were categorized as having severely elevated INR (INR>12). In addition, ΔINRs associated with these INRs were 2.15±0.9, 5.5±1.9, and 9.6±4.7, respectively. As Table 2 shows, the differences among all groups were statistically significant (ANOVA, Tamhane, p<0.001). As Figure 1 shows, there was a strong positive correlation between high pre-transfusion INRs and ΔINR (p<0.001, r=0.85). Regression analysis performed to estimate ΔINR after transfusion of a standard dose of FFP found that ΔINR=0.69×(pre-transfusion INR)−1.111 (p<0.001).
Finally, when the data were analyzed according to laboratory outcomes (post-transfusion INR) and clinical outcomes (re-bleeding or unstoppable bleeding), 12 patients' post-transfusion INRs could not be decreased to either therapeutic or normal levels. However, no patients required a second 2-unit FFP transfusion, and no patients experienced re-bleeding or unstoppable bleeding.
Discussion
This study aimed to detect whether transfusion with a standard dose of FFP decreased INRs in patients whose INRs were elevated due to warfarin use. The study identified two important results. First, it appears that using a standard dose of FFP causes varying reductions in ΔINRs in patients whose pre-transfusion 
Comorbid diseases, n (%)
• Hypertension 24 (75)
• Coronary artery disease 16 (50)
• Diabetes mellitus 14 (43.8)
• Congestive heart disease 12 (37.5)
• Chronic kidney disease 2 (6.3)
• Other 9 (28)
Vital signs (mean±SD)
• Systolic blood pressure, mmHg 125±26
• Diastolic blood pressure, mmHg 68±13
• Heart rate, beats/min 91±11 Indication for using warfarin, n (%)
• Atrial fibrillation 15 (47)
• Venous thromboembolism 7 (22)
• Heart valve replacement 6 (19)
• Other 4 (12)
Indication for FFP transfusion, n (%)
• INRs are elevated to various degrees. Second, despite this first result, using a standard dose of FFP may fail to reduce INRs to therapeutic levels. In 12 patients, post-transfusion INRs could not be decreased to therapeutic levels. However, none of these 12 patients had indications requiring a second FFP transfusion because none of the patients experienced re-bleeding or unstoppable bleeding. Therefore, the findings of the study appear to indicate that a standard dose of FFP is sufficient to safely reduce INRs in patients with both elevated INRs and indications for FFP transfusion. Of course, it must be taken into consideration that this study had a small population; thus, the results may not be enough to extrapolate from.
Two studies, Abdel-Wahab et al. (10) (14) . As in these previous studies, the present study found a strong positive correlation between elevated pre-transfusion INRs and ΔINR. In addition, the present study performed a regression analysis to estimate ΔINR after transfusion of a standard dose of FFP (3 units) and found that ΔINR=0.69×(pre-transfusion INR)−1.111.
Currently, modern guidelines recommend prothrombin complex concentrate (PCC) (50 units/kg) as the first option in reversing the effects of warfarin. FFP is only recommended if there is major bleeding and PCC is unavailable. However, PCC is unavailable in our hospital; thus, we have to use FFP to reverse the effects of warfarin.
Study limitations
The most significant limitation of this study was the small population size. In addition, our study was an observational prospective study and not a randomized controlled study. Our study group mainly comprised geriatric patients who use multi-drugs and have co-morbidities. Therefore, the results may not be sufficient to extrapolate from.
Conclusion
The present study found that using a standard dose of FFP caused varying reductions in ΔINRs with correlated pre-transfusion INRs in patients whose INRs were elevated to varying degrees before transfusion. However, FFP may fail to reduce INRs to therapeutic levels. Considering that none of the patients in the present study experienced re-bleeding or unstoppable bleeding, the findings indicate that a standard dose of FFP is sufficient to safely reduce INRs in patients who have both elevated INRs and indications for FFP transfusion.
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